feb 12, 2018: 5 p.m. - 5:55 p.m.
With more than 30 biotech IPOs in 2017 but M&A deal activity running at lower than average levels, the tension for CEOs is delivering a confident story of how to achieve profitable growth for investors while drug launches receive more scrutiny than ever. As large biopharmas prune their portfolios and consider their repatriation options, the expectations run high for an uptick in M&A in 2018. This session will include experienced deal makers and investors sharing their perspectives on where they see the promise of intensifying activity within the industry this year.
Moderator: Stephen B. Thau, Partner, Morrison & Foerster LLP
James Cappuccio, Managing Director, H.C. Wainwright and Co., LLC
Chris Garabedian, Chairman and CEO, Xontogeny
Stefan D. Loren, PhD, Managing Director, Healthcare Investment Banking, Oppenheimer & Co.
Michael Meyers, Head of Investment Banking, T. R. Winston & Company; Interim Chief Executive Officer, Tivorsan Pharmaceuticals, Inc.
Matthew Roden, PhD, Head of Strategic Corporate Development and Global BD Assessment, Bristol-Myers Squibb
Sapna Srivastava, PhD, Chief Financial Officer and Chief Strategy Officer, Abide Therapeutics